Improvement of quality of lives of patients suffering from strokes and aneurysms is possible. Thanks to extensive R&D activities and launch of new neurovascular devices.
Improvement of quality of lives of patients suffering from strokes and aneurysms is possible. Thanks to extensive R&D activities and launch of new neurovascular devices. Manufacturers have been raising funding to bring new products and commercialize innovative technologies. In addition, some of the manufacturers have been consulting with the experts in the field and developing products to shorten delivery time and facilitate the treatment. There will be more life-saving and innovative products in the market in the coming years. According to the report published by Allied Market Research, the global neurovascular devices market is estimated to reach $3.71 billion by 2027. Following are some of the activities taking place across the world.
Neurovascular device manufacturers adopted various strategies to develop and commercialize new products. One of the leading next-generation neurovascular device manufacturers Perfuze raised €22.5 million in a Series A funding. The round was led by LSP and Seroba Life Sciences. The newly-raised funding will be utilized for developing new products and commercialization of innovative technology for treatment of acute ischemic stroke. In addition, the funding will be utilized for taking the clinical study to the next stage and gain regulatory approval for its Millipede System.
The Millipede System enables quick and efficient blood vessel recanalization. This is essential for improvement of functional status of patients and lower down the mortality following a stroke event. One of the investors LSP highlighted that Perfuze possesses a technology that can improve the outcomes of stroke patients considerably. The investor intends to help the company in expansion and bringing life-saving technologies to the market.
Download Sample Report- https://www.alliedmarketresearch.com/request-sample/2278
Along with raising funding, the launch of new devices is one of the major trends taking place across the world. Evasc Neurovascular announced the launch of eCLIPs Bifurcation Flow Diverter. This new device is a flow diverter that provides a leaf density of 35% and does not need coiling. Moreover, it simplifies the deployment and lowers down the delivery time. Dr. Donald Ricci, the President and Chief Executive Officer of Evasc Neurovascular, outlined that the company consulted with the experts in the neuro sector and developed a smaller and easier to utilize version of its device. The new device will be useful in the treatment for a wide range of aneurysms. In addition, it will reduce the delivery time. This device will also provide access to minute and more distant vessels in the cerebral anatomy and facilitate the treatment. The launch of innovative and improved devices is expected to continue in the coming years.